Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Patrys Limited ( (AU:PAB) ) just unveiled an update.
Patrys Limited has completed a $308,362 capital raise and restructured its board and management to focus on out-licensing its deoxymab assets and exploring new pipeline opportunities. The company is actively pursuing partnerships and licensing opportunities for its assets, with ongoing evaluations to diversify shareholder risk and support long-term value. The recent financial activities, including a capital raise and an expected R&D Tax Incentive refund, aim to provide financial stability for continued business development and operational activities.
More about Patrys Limited
Based in Melbourne, Australia, Patrys Limited (ASX:PAB) is a therapeutic antibody development company focused on its deoxymab platform of cell-penetrating antibodies for various indications.
Technical Sentiment Signal: Strong Sell
Current Market Cap: A$4.73M
See more insights into PAB stock on TipRanks’ Stock Analysis page.